Research Article
The epidemiology of Alzheimer‘s disease: Laying the foundation for drug design, conduct, and analysis of clinical trials

Kristine Yaffe, Michael Tocco, Ronald C. Petersen, Catherine Sigler, Leah C. Burns, Christel Cornelius, Ara S. Khachaturian, Michael C. Irizarry and Maria C. Carrillo

Alzheimer`s & Dementia, 2012, 8(3), 237-242. DOI: 10.1016/j.jalz.2011.12.005

Abstract

Epidemiological studies increasingly inform Alzheimer‘s disease (AD) public health impact, prevention strategies, drug targets, therapeutic interventions, and clinical trial design. For this reason, the Alzheimer‘s Association Research Roundtable convened an international group of AD experts with experience in conducting both observational and clinical trials for a meeting on October 19 and 20, 2010, in Washington, DC, to discuss the role of epidemiologic studies in AD research and therapeutic advances. Topics included wellness markers and risk factors, with a focus on special populations such as those at elevated risk, super agers, and underserved populations. Discussions also highlighted lessons learned from observational studies of aging, cardiovascular disease, and other disease areas, as well as how new technologies have enabled the gathering of data relevant to drug development and clinical trial conduct.

ASCI-ID: 285-196

View Fulltext

Similar Articles


Fluorodeoxyglucose positron emission tomography of mild cognitive impairment with clinical follow-up at 3 years

Alzheimer`s & Dementia, 2010, 6(4), 326-333. DOI: 10.1016/j.jalz.2009.09.005

Commentary on “A roadmap for the prevention of dementia II: Leon Thal Symposium 2008.” A national registry on aging

Alzheimer`s & Dementia, 2009, 5(2), 105-107. DOI: 10.1016/j.jalz.2009.01.010

Dementia and Alzheimer‘s disease: A new direction. The 2010 Jay L. Foster Memorial Lecture

Alzheimer`s & Dementia, 2011, 7(5), 540-550. DOI: 10.1016/j.jalz.2011.05.901

A homopolymer polymorphism in the TOMM40 gene contributes to cognitive performance in aging

Alzheimer`s & Dementia, 2012, 8(5), 381-388. DOI: 10.1016/j.jalz.2011.10.005

Review of selected databases of longitudinal aging studies

Alzheimer`s & Dementia, 2012, 8(6), 584-589. DOI: 10.1016/j.jalz.2011.09.232

Alzheimer's disease pathology does not mediate the association between depressive symptoms and subsequent cognitive decline

Alzheimer`s & Dementia, 2013, 9(3), 318-325. DOI: 10.1016/j.jalz.2011.11.009

A European perspective on population studies of dementia

Alzheimer`s & Dementia, 2011, 7(1), 3-9. DOI: 10.1016/j.jalz.2010.12.003

Operationalizing diagnostic criteria for Alzheimer‘s disease and other age-related cognitive impairment–Part 2

Alzheimer`s & Dementia, 2011, 7(1), 35-52. DOI: 10.1016/j.jalz.2010.12.002

Sources of variability in estimates of the prevalence of Alzheimer‘s disease in the United States

Alzheimer`s & Dementia, 2011, 7(1), 74-79. DOI: 10.1016/j.jalz.2010.11.006

Transforming cerebrospinal fluid Aβ42 measures into calculated Pittsburgh compound B units of brain Aβ amyloid

Alzheimer`s & Dementia, 2011, 7(2), 133-141. DOI: 10.1016/j.jalz.2010.08.230

Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

Alzheimer`s & Dementia, 2011, 7(3), 257-262. DOI: 10.1016/j.jalz.2011.03.004

The Alzheimer‘s Association external quality control program for cerebrospinal fluid biomarkers

Alzheimer`s & Dementia, 2011, 7(4), 386-395. DOI: 10.1016/j.jalz.2011.05.2243

Prevalence of asymptomatic vasogenic edema in pretreatment Alzheimer‘s disease study cohorts from phase 3 trials of semagacestat and solanezumab

Alzheimer`s & Dementia, 2011, 7(4), 396-401. DOI: 10.1016/j.jalz.2011.05.2353

Extended results of the Alzheimer‘s disease anti-inflammatory prevention trial

Alzheimer`s & Dementia, 2011, 7(4), 402-411. DOI: 10.1016/j.jalz.2010.12.014

Magnetic resonance imaging and neuropsychological results from a trial of memantine in Alzheimer‘s disease

Alzheimer`s & Dementia, 2011, 7(4), 425-435. DOI: 10.1016/j.jalz.2010.09.003

Intracranial atherosclerosis as a contributing factor to Alzheimer‘s disease dementia

Alzheimer`s & Dementia, 2011, 7(4), 436-444. DOI: 10.1016/j.jalz.2010.08.228

Transcranial Doppler ultrasound blood flow velocity and pulsatility index as systemic indicators for Alzheimer‘s disease

Alzheimer`s & Dementia, 2011, 7(4), 445-455. DOI: 10.1016/j.jalz.2010.09.002

The effect of TOMM40 poly-T length on gray matter volume and cognition in middle-aged persons with APOE ɛ3/ɛ3 genotype

Alzheimer`s & Dementia, 2011, 7(4), 456-465. DOI: 10.1016/j.jalz.2010.11.012

Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criterion for Alzheimer‘s disease

Alzheimer`s & Dementia, 2011, 7(4), 474-485. DOI: 10.1016/j.jalz.2011.04.007

Magnetic resonance imaging-measured atrophy and its relationship to cognitive functioning in vascular dementia and Alzheimer‘s disease patients

Alzheimer`s & Dementia, 2011, 7(5), 493-500. DOI: 10.1016/j.jalz.2011.01.004

Frequency of Alzheimer‘s disease pathology at autopsy in patients with clinical normal pressure hydrocephalus

Alzheimer`s & Dementia, 2011, 7(5), 509-513. DOI: 10.1016/j.jalz.2010.12.008

Long-term progression of Alzheimer‘s disease in patients under antidementia drugs

Alzheimer`s & Dementia, 2011, 7(6), 579-592. DOI: 10.1016/j.jalz.2011.02.009

The measurement of everyday cognition: Development and validation of a short form of the Everyday Cognition scales

Alzheimer`s & Dementia, 2011, 7(6), 593-601. DOI: 10.1016/j.jalz.2011.02.007

Suitability of the Clinical Dementia Rating-Sum of Boxes as a single primary endpoint for Alzheimer‘s disease trials

Alzheimer`s & Dementia, 2011, 7(6), 602-610. DOI: 10.1016/j.jalz.2011.01.005

An economic evaluation of early assessment for Alzheimer‘s disease in the United Kingdom

Alzheimer`s & Dementia, 2012, 8(1), 22-30. DOI: 10.1016/j.jalz.2010.07.001

Modeling Alzheimer‘s disease progression using the disease system analysis approach

Alzheimer`s & Dementia, 2012, 8(1), 39-50. DOI: 10.1016/j.jalz.2010.12.012

Direct comparison of fluorodeoxyglucose positron emission tomography and arterial spin labeling magnetic resonance imaging in Alzheimer's disease

Alzheimer`s & Dementia, 2012, 8(1), 51-59. DOI: 10.1016/j.jalz.2011.06.003

Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization Initiative

Alzheimer`s & Dementia, 2012, 8(1), 65-73. DOI: 10.1016/j.jalz.2011.07.004

[123I]N-ω-fluoropropyl-2β-carbomethoxy-3β-(4-iodophenyl)nortropane single-photon emission computed tomography brain imaging in the diagnosis of dementia with Lewy bodies

Alzheimer`s & Dementia, 2012, 8(1), 74-83. DOI: 10.1016/j.jalz.2011.08.003

An investigation of PreMCI: Subtypes and longitudinal outcomes

Alzheimer`s & Dementia, 2012, 8(3), 172-179. DOI: 10.1016/j.jalz.2011.03.002

Serum antibodies to periodontal pathogens are a risk factor for Alzheimer‘s disease

Alzheimer`s & Dementia, 2012, 8(3), 196-203. DOI: 10.1016/j.jalz.2011.04.006

Cognitive and structural magnetic resonance imaging features of Lewy body dementia and Alzheimer‘s disease

Alzheimer`s & Dementia, 2012, 8(3), 211-218. DOI: 10.1016/j.jalz.2011.04.008

Nonsteroidal anti-inflammatory drug use and the risk of cognitive impairment and Alzheimer‘s disease

Alzheimer`s & Dementia, 2012, 8(3), 219-226. DOI: 10.1016/j.jalz.2011.03.012

Alzheimer‘s disease: Pathogenesis and prevention

Alzheimer`s & Dementia, 2012, 8(3), 227-233. DOI: 10.1016/j.jalz.2012.01.011

Safety and biomarker effects of solanezumab in patients with Alzheimer‘s disease

Alzheimer`s & Dementia, 2012, 8(4), 261-271. DOI: 10.1016/j.jalz.2011.09.224

Leptin and dementia over 32 years–The Prospective Population Study of Women

Alzheimer`s & Dementia, 2012, 8(4), 272-277. DOI: 10.1016/j.jalz.2011.05.2411

Gaining precision on the Alzheimer‘s Disease Assessment Scale-cognitive: A comparison of item response theory-based scores and total scores

Alzheimer`s & Dementia, 2012, 8(4), 288-294. DOI: 10.1016/j.jalz.2011.05.2409

Effect of human cerebrospinal fluid sampling frequency on amyloid-β levels

Alzheimer`s & Dementia, 2012, 8(4), 295-303. DOI: 10.1016/j.jalz.2011.05.900

Worldwide Alzheimer‘s Disease Neuroimaging Initiative

Alzheimer`s & Dementia, 2012, 8(4), 337-342. DOI: 10.1016/j.jalz.2012.04.007

Some evolutionary perspectives on Alzheimer‘s disease pathogenesis and pathology

Alzheimer`s & Dementia, 2012, 8(4), 343-351. DOI: 10.1016/j.jalz.2011.05.2408

Cardiovascular fitness is associated with altered cortical glucose metabolism during working memory in ɛ4 carriers

Alzheimer`s & Dementia, 2012, 8(4), 352-356. DOI: 10.1016/j.jalz.2011.04.010

Common Alzheimer‘s Disease Research Ontology: National Institute on Aging and Alzheimer‘s Association Collaborative Project

Alzheimer`s & Dementia, 2012, 8(4), 372-375. DOI: 10.1016/j.jalz.2012.05.2115

A homopolymer polymorphism in the TOMM40 gene contributes to cognitive performance in aging

Alzheimer`s & Dementia, 2012, 8(5), 381-388. DOI: 10.1016/j.jalz.2011.10.005

Amyloid imaging in dementias with atypical presentation

Alzheimer`s & Dementia, 2012, 8(5), 389-398. DOI: 10.1016/j.jalz.2011.07.003

Comparing new templates and atlas-based segmentations in the volumetric analysis of brain magnetic resonance images for diagnosing Alzheimer‘s disease

Alzheimer`s & Dementia, 2012, 8(5), 399-406. DOI: 10.1016/j.jalz.2011.07.002

Safety profile of Alzheimer's disease populations in Alzheimer's Disease Neuroimaging Initiative and other 18-month studies

Alzheimer`s & Dementia, 2012, 8(5), 407-416. DOI: 10.1016/j.jalz.2011.05.2413

Imaging brain amyloid in nondemented young adults with Down syndrome using Pittsburgh compound B

Alzheimer`s & Dementia, 2012, 8(6), 496-501. DOI: mailto:[email protected]

Greater regional brain atrophy rate in healthy elderly subjects with a history of cigarette smoking

Alzheimer`s & Dementia, 2012, 8(6), 513-519. DOI: 10.1016/j.jalz.2011.10.006

Differential prediction of vascular dementia and Alzheimer‘s disease in nondemented older adults within 5 years of initial testing

Alzheimer`s & Dementia, 2012, 8(6), 528-535. DOI: 10.1016/j.jalz.2011.09.233

A new informant-based questionnaire for instrumental activities of daily living in dementia

Alzheimer`s & Dementia, 2012, 8(6), 536-543. DOI: 10.1016/j.jalz.2011.08.006

Comparison of International Working Group criteria and National Institute on Aging–Alzheimer‘s Association criteria for Alzheimer‘s disease

Alzheimer`s & Dementia, 2012, 8(6), 560-563. DOI: 10.1016/j.jalz.2011.10.008

Association of environmental tobacco smoke with dementia and Alzheimer‘s disease among never smokers

Alzheimer`s & Dementia, 2012, 8(6), 590-595. DOI: 10.1016/j.jalz.2011.09.231

The worldwide economic impact of dementia 2010

Alzheimer`s & Dementia, 2013, 9(1), 1-11. DOI: 10.1016/j.jalz.2012.11.006

Apolipoprotein E genotype, dementia, and mortality in the oldest old: The 90+ Study

Alzheimer`s & Dementia, 2013, 9(1), 12-18. DOI: 10.1016/j.jalz.2011.12.004

Potentially avoidable hospitalizations among Medicare beneficiaries with Alzheimer‘s disease and related disorders

Alzheimer`s & Dementia, 2013, 9(1), 30-38. DOI: 10.1016/j.jalz.2012.11.002

The economics of mild cognitive impairment

Alzheimer`s & Dementia, 2013, 9(1), 58-62. DOI: 10.1016/j.jalz.2012.05.2117

Frailty syndrome and the risk of vascular dementia: The Italian Longitudinal Study on Aging

Alzheimer`s & Dementia, 2013, 9(2), 113-122. DOI: 10.1016/j.jalz.2011.09.223

Intracerebral propagation of Alzheimer‘s disease: Strengthening evidence of a herpes simplex virus etiology

Alzheimer`s & Dementia, 2013, 9(2), 169-175. DOI: 10.1016/j.jalz.2012.07.005

Phenotypic regional functional imaging patterns during memory encoding in mild cognitive impairment and Alzheimer's disease

Alzheimer`s & Dementia, 2013, 9(3), 284-294. DOI: 10.1016/j.jalz.2011.12.006

Effectiveness of antidementia drugs in delaying Alzheimer's disease progression

Alzheimer`s & Dementia, 2013, 9(3), 338-345. DOI: 10.1016/j.jalz.2012.01.002

Risk disclosure and preclinical Alzheimer‘s disease clinical trial enrollment

Alzheimer`s & Dementia, 2013, 9(3), 356-359. DOI: 10.1016/j.jalz.2012.03.001

β-Site amyloid precursor protein–cleaving enzyme 1 activity is related to cerebrospinal fluid concentrations of sortilin-related receptor with A-type repeats, soluble amyloid precursor protein, and tau

Alzheimer`s & Dementia, 2013, 9(4), 386-391. DOI: 10.1016/j.jalz.2012.01.015

Physician outpatient contacts and hospitalizations among cognitively impaired elderly

Alzheimer`s & Dementia, 2009, 5(1), 30-42. DOI: 10.1016/j.jalz.2008.05.2493

Dementia literacy: Recognition and beliefs on dementia of the Australian public

Alzheimer`s & Dementia, 2009, 5(1), 43-49. DOI: 10.1016/j.jalz.2008.03.011

Associations among measures of awareness of cognitive deficits in dementia

Alzheimer`s & Dementia, 2010, 6(4), 312-318. DOI: 10.1016/j.jalz.2009.06.005

A roadmap for the prevention of dementia II: Leon Thal Symposium 2008

Alzheimer`s & Dementia, 2009, 5(2), 85-92. DOI: 10.1016/j.jalz.2009.01.021

Commentary on “A roadmap for the prevention of dementia II: Leon Thal Symposium 2008.” A national registry on aging

Alzheimer`s & Dementia, 2009, 5(2), 105-107. DOI: 10.1016/j.jalz.2009.01.010

Commentary on `A roadmap for the prevention of dementia II: Leon Thal Symposium 2008.` Establishing a national biomarker database: Utility and incentives

Alzheimer`s & Dementia, 2009, 5(2), 108-113. DOI: 10.1016/j.jalz.2009.01.015

Commentary on `A roadmap for the prevention of dementia II. Leon Thal Symposium 2008.` Facilitating Alzheimer's disease drug development in the United States

Alzheimer`s & Dementia, 2009, 5(2), 125-127. DOI: 10.1016/j.jalz.2009.01.005

Commentary on “A roadmap for the prevention of dementia II. Leon Thal Symposium 2008.” A national registry to identify a cohort for Alzheimer's disease prevention studies

Alzheimer`s & Dementia, 2009, 5(2), 128-129. DOI: 10.1016/j.jalz.2009.01.018

Commentary on `A roadmap for the prevention of dementia II. Leon Thal Symposium 2008.` Alzheimer's disease translational research programs at the National Institute on Aging

Alzheimer`s & Dementia, 2009, 5(2), 130-132.

Commentary on ”map for the prevention of dementia II: Leon Thal Symposium 2008.” ”Big Asks”: What can be changed to increase and speed progress on Alzheimer's disease research and treatment?

Alzheimer`s & Dementia, 2009, 5(2), 137-139. DOI: 10.1016/j.jalz.2009.01.003

Commentary on ”A roadmap for the prevention of dementia II: Leon Thal Symposium 2008.“ A proposal to increase participation in Alzheimer's disease clinical trials

Alzheimer`s & Dementia, 2009, 5(2), 140-142. DOI: 10.1016/j.jalz.2009.01.004

Commentary on ”A roadmap for the prevention of dementia II. Leon Thal Symposium 2008.“ Rationale and recommendations for first evaluating anti-Alzheimer's disease medications in acute brain injury patients

Alzheimer`s & Dementia, 2009, 5(2), 143-146. DOI: 10.1016/j.jalz.2009.01.013

Commentary on ”A roadmap for the prevention of dementia II. Leon Thal Symposium 2008.“ Who may benefit from disease-modifying studies in Alzheimer's disease?

Alzheimer`s & Dementia, 2009, 5(2), 147-148. DOI: 10.1016/j.jalz.2009.01.007

Commentary on ”A roadmap for the prevention of dementia II. Leon Thal Symposium 2008.“ Primary prevention of dementia in Alzheimer's disease: A perspective from prevention research in cardiovascular disease and stroke

Alzheimer`s & Dementia, 2009, 5(2), 149-153. DOI: 10.1016/j.jalz.2009.01.012

Commentary on ”A roadmap for the prevention of dementia II. Leon Thal Symposium 2008.“ Primary prevention of dementia in Alzheimer's disease: A perspective from prevention research in cardiovascular disease and stroke

Alzheimer`s & Dementia, 2009, 5(2), 149-153. DOI: 10.1016/j.jalz.2009.01.012

Commentary on ”A roadmap for the prevention of dementia II: Leon Thal Symposium 2008.“ Subjective cognitive impairment as an antecedent of Alzheimer's dementia: Policy import

Alzheimer`s & Dementia, 2009, 5(2), 154-156. DOI: 10.1016/j.jalz.2009.01.011

Commentary on ”A roadmap for the prevention of dementia II: Leon Thal Symposium 2008.“ Subjective cognitive impairment as an antecedent of Alzheimer's dementia: Policy import

Alzheimer`s & Dementia, 2009, 5(2), 154-156. DOI: 10.1016/j.jalz.2009.01.011

Commentary on ”A roadmap for the prevention of dementia II: Leon Thal Symposium 2008.“ Comments from abroad

Alzheimer`s & Dementia, 2009, 5(2), 157-158. DOI: 10.1016/j.jalz.2009.01.009

Commentary on ” A roadmap for the prevention of dementia II: Leon Thal symposium 2008.“ The megacommunity approach to Alzheimer's disease

Alzheimer`s & Dementia, 2009, 5(2), 163-165. DOI: 10.1016/j.jalz.2009.02.002

Commentary on ” A roadmap for the prevention of dementia II: Leon Thal Symposium 2008.“ Prevention trials in persons at risk for dominantly inherited Alzheimer's disease: Opportunities and challenges

Alzheimer`s & Dementia, 2009, 5(2), 166-171. DOI: 10.1016/j.jalz.2008.12.002

Commentary on ”A roadmap for the prevention of dementia II: Leon Thal Symposium 2008.“A federally funded corporation for the prevention and treatment of cognitive impairment and brain aging

Alzheimer`s & Dementia, 2009, 5(2), 172-179. DOI: 10.1016/j.jalz.2009.01.023

Elevated C-reactive protein levels are associated with prevalent dementia in the oldest-old

Alzheimer`s & Dementia, 2009, 5(4), 318-323. DOI: 10.1016/j.jalz.2009.04.1230

Cognitive performance and informant reports in the diagnosis of cognitive impairment and dementia in African Americans and whites

Alzheimer`s & Dementia, 2009, 5(6), 445-453. DOI: 10.1016/j.jalz.2009.04.1234

Closing the dementia care gap: Can referral to Alzheimer's Association chapters help?

Alzheimer`s & Dementia, 2009, 5(6), 498-502. DOI: 10.1016/j.jalz.2009.01.024

Outcome over seven years of healthy adults with and without subjective cognitive impairment

Alzheimer`s & Dementia, 2010, 6(1), 11-24. DOI: 10.1016/j.jalz.2009.10.002

White matter integrity and cortical metabolic associations in aging and dementia

Alzheimer`s & Dementia, 2010, 6(1), 54-62. DOI: 10.1016/j.jalz.2009.04.1228

Rivastigmine for the treatment of dementia in patients with progressive supranuclear palsy: Clinical observations as a basis for power calculations and safety analysis

Alzheimer`s & Dementia, 2010, 6(1), 70-74. DOI: 10.1016/j.jalz.2009.04.1231

Early dementia diagnosis and the risk of suicide and euthanasia

Alzheimer`s & Dementia, 2010, 6(1), 75-82. DOI: 10.1016/j.jalz.2009.04.1229

The worldwide societal costs of dementia: Estimates for 2009

Alzheimer`s & Dementia, 2010, 6(2), 98-103. DOI: 10.1016/j.jalz.2010.01.010

A European perspective on population studies of dementia

Alzheimer`s & Dementia, 2011, 7(1), 3-9. DOI: 10.1016/j.jalz.2010.12.003

Counting dementia: There is no one ”best“ way

Alzheimer`s & Dementia, 2011, 7(1), 10-14. DOI: 10.1016/j.jalz.2010.11.003

Operationalizing diagnostic criteria for Alzheimer‘s disease and other age-related cognitive impairment–Part 2

Alzheimer`s & Dementia, 2011, 7(1), 35-52. DOI: 10.1016/j.jalz.2010.12.002

Sources of variability in estimates of the prevalence of Alzheimer‘s disease in the United States

Alzheimer`s & Dementia, 2011, 7(1), 74-79. DOI: 10.1016/j.jalz.2010.11.006

Serum homocysteine and dementia: Meta-analysis of eight cohort studies including 8669 participants

Alzheimer`s & Dementia, 2011, 7(4), 412-417. DOI: 10.1016/j.jalz.2010.08.234

How golden is the gold standard of neuropathology in dementia?

Alzheimer`s & Dementia, 2011, 7(4), 486-489. DOI: 10.1016/j.jalz.2011.04.011

Magnetic resonance imaging-measured atrophy and its relationship to cognitive functioning in vascular dementia and Alzheimer‘s disease patients

Alzheimer`s & Dementia, 2011, 7(5), 493-500. DOI: 10.1016/j.jalz.2011.01.004

Frequency of Alzheimer‘s disease pathology at autopsy in patients with clinical normal pressure hydrocephalus

Alzheimer`s & Dementia, 2011, 7(5), 509-513. DOI: 10.1016/j.jalz.2010.12.008

Dementia and Alzheimer‘s disease: A new direction. The 2010 Jay L. Foster Memorial Lecture

Alzheimer`s & Dementia, 2011, 7(5), 540-550. DOI: 10.1016/j.jalz.2011.05.901

Videoconference diagnosis and management of Choctaw Indian dementia patients

Alzheimer`s & Dementia, 2011, 7(6), 562-566. DOI: 10.1016/j.jalz.2011.02.006

Predictors of suicide in patients with dementia

Alzheimer`s & Dementia, 2011, 7(6), 567-573. DOI: 10.1016/j.jalz.2011.01.006

Functional deficits among patients with mild cognitive impairment

Alzheimer`s & Dementia, 2011, 7(6), 611-614. DOI: 10.1016/j.jalz.2010.12.011

Direct comparison of fluorodeoxyglucose positron emission tomography and arterial spin labeling magnetic resonance imaging in Alzheimer's disease

Alzheimer`s & Dementia, 2012, 8(1), 51-59. DOI: 10.1016/j.jalz.2011.06.003

Psychosocial stress at work is associated with increased dementia risk in late life

Alzheimer`s & Dementia, 2012, 8(2), 114-120. DOI: 10.1016/j.jalz.2011.03.001

Some evolutionary perspectives on Alzheimer‘s disease pathogenesis and pathology

Alzheimer`s & Dementia, 2012, 8(4), 343-351. DOI: 10.1016/j.jalz.2011.05.2408

Analysis of case management programs for patients with dementia: A systematic review

Alzheimer`s & Dementia, 2012, 8(5), 426-436. DOI: 10.1016/j.jalz.2011.06.004

Antihypertensive drug use and the risk of dementia in patients with diabetes mellitus

Alzheimer`s & Dementia, 2012, 8(5), 437-444. DOI: 10.1016/j.jalz.2011.05.2414

Impact of the Food and Drug Administration‘s antipsychotic black box warning on psychotropic drug prescribing in elderly patients with dementia in outpatient and office-based settings

Alzheimer`s & Dementia, 2012, 8(5), 453-457. DOI: 10.1016/j.jalz.2011.08.004

Predictive validity and diagnostic stability of mild cognitive impairment subtypes

Alzheimer`s & Dementia, 2012, 8(6), 553-559.

Association of environmental tobacco smoke with dementia and Alzheimer‘s disease among never smokers

Alzheimer`s & Dementia, 2012, 8(6), 590-595. DOI: 10.1016/j.jalz.2011.09.231

The worldwide economic impact of dementia 2010

Alzheimer`s & Dementia, 2013, 9(1), 1-11. DOI: 10.1016/j.jalz.2012.11.006

Apolipoprotein E genotype, dementia, and mortality in the oldest old: The 90+ Study

Alzheimer`s & Dementia, 2013, 9(1), 12-18. DOI: 10.1016/j.jalz.2011.12.004

Dementia and out-of-pocket spending on health care services

Alzheimer`s & Dementia, 2013, 9(1), 19-29. DOI: 10.1016/j.jalz.2011.11.003

The global prevalence of dementia: A systematic review and metaanalysis

Alzheimer`s & Dementia, 2013, 9(1), 63-75. DOI: 10.1016/j.jalz.2012.11.007

Vascular disease and dementias: Paradigm shifts to drive research in new directions

Alzheimer`s & Dementia, 2013, 9(1), 76-92. DOI: 10.1016/j.jalz.2012.02.007

Frailty syndrome and the risk of vascular dementia: The Italian Longitudinal Study on Aging

Alzheimer`s & Dementia, 2013, 9(2), 113-122. DOI: 10.1016/j.jalz.2011.09.223

Alzheimer's Association recommendations for operationalizing the detection of cognitive impairment during the Medicare Annual Wellness Visit in a primary care setting

Alzheimer`s & Dementia, 2013, 9(2), 141-150. DOI: 10.1016/j.jalz.2012.09.011

Improving dementia care: The role of screening and detection of cognitive impairment

Alzheimer`s & Dementia, 2013, 9(2), 151-159. DOI: 10.1016/j.jalz.2012.08.008

A prediction model to calculate probability of Alzheimer‘s disease using cerebrospinal fluid biomarkers

Alzheimer`s & Dementia, 2013, 9(3), 262-268. DOI: 10.1016/j.jalz.2012.01.010

Mild cognitive impairment in a community sample: The Sydney Memory and Ageing Study

Alzheimer`s & Dementia, 2013, 9(3), 310-317. DOI: 10.1016/j.jalz.2011.11.010

Prevalence of mild cognitive impairment subtypes in patients attending a memory outpatient clinic—comparison of two modes of mild cognitive impairment classification. Results of the Vienna Conversion to Dementia Study

Alzheimer`s & Dementia, 2013, 9(4), 366-376. DOI: 10.1016/j.jalz.2011.12.009

Long–term anticholinergic use and the aging brain

Alzheimer`s & Dementia, 2013, 9(4), 377-385. DOI: 10.1016/j.jalz.2012.02.005

β-Site amyloid precursor protein–cleaving enzyme 1 activity is related to cerebrospinal fluid concentrations of sortilin-related receptor with A-type repeats, soluble amyloid precursor protein, and tau

Alzheimer`s & Dementia, 2013, 9(4), 386-391. DOI: 10.1016/j.jalz.2012.01.015

Risk of Alzheimer's disease incidence attributable to vascular disease in the population

Alzheimer`s & Dementia, 2011, 7(3), 356-360. DOI: 10.1016/j.jalz.2010.12.004

Dementia and Alzheimer‘s disease: A new direction. The 2010 Jay L. Foster Memorial Lecture

Alzheimer`s & Dementia, 2011, 7(5), 540-550. DOI: 10.1016/j.jalz.2011.05.901

Mild cognitive impairment: Disparity of incidence and prevalence estimates

Alzheimer`s & Dementia, 2012, 8(1), 14-21. DOI: 10.1016/j.jalz.2011.01.002

Safety profile of Alzheimer's disease populations in Alzheimer's Disease Neuroimaging Initiative and other 18-month studies

Alzheimer`s & Dementia, 2012, 8(5), 407-416. DOI: 10.1016/j.jalz.2011.05.2413

Vascular risk factors, apolipoprotein E, and hippocampal decline on magnetic resonance imaging over a 10-year follow-up

Alzheimer`s & Dementia, 2012, 8(5), 417-425. DOI: 10.1016/j.jalz.2011.07.005

No association between gain in body mass index across the life course and midlife cognitive function and cognitive reserve–The 1946 British birth cohort study

Alzheimer`s & Dementia, 2012, 8(6), 470-482. DOI: 10.1016/j.jalz.2011.09.228

The global prevalence of dementia: A systematic review and metaanalysis

Alzheimer`s & Dementia, 2013, 9(1), 63-75. DOI: 10.1016/j.jalz.2012.11.007

The basis for disease-modifying treatments for Alzheimer`s disease: The Sixth Annual Mild Cognitive Impairment Symposium

Alzheimer`s & Dementia, 2009, 5(1), 66-74. DOI: 10.1016/j.jalz.2008.10.006

Requiring an amyloid-β1-42 biomarker for prodromal Alzheimer’s disease or mild cognitive impairment does not lead to more efficient clinical trials

Alzheimer`s & Dementia, 2010, 6(5), 367-377. DOI: 10.1016/j.jalz.2010.07.004

Plasma ceramides are altered in mild cognitive impairment and predict cognitive decline and hippocampal volume loss

Alzheimer`s & Dementia, 2010, 6(5), 378-385. DOI: 10.1016/j.jalz.2010.03.014

Update on the biomarker core of the Alzheimer’s Disease Neuroimaging Initiative subjects

Alzheimer`s & Dementia, 2010, 6(3), 230-238. DOI: 10.1016/j.jalz.2010.03.008

The Alzheimer’s Disease Neuroimaging Initiative: Annual change in biomarkers and clinical outcomes

Alzheimer`s & Dementia, 2010, 6(3), 257-264. DOI: 10.1016/j.jalz.2010.03.002

Addressing population aging and Alzheimer’s disease through the Australian Imaging Biomarkers and Lifestyle study: Collaboration with the Alzheimer’s Disease Neuroimaging Initiative

Alzheimer`s & Dementia, 2010, 6(3), 291-296. DOI: 10.1016/j.jalz.2010.03.009

Atypical event-related potentials in patients with mild cognitive impairment: An identification-priming study

Alzheimer`s & Dementia, 2010, 6(4), 351-358. DOI: 10.1016/j.jalz.2009.05.664

Association of C-reactive protein with mild cognitive impairment

Alzheimer`s & Dementia, 2009, 5(5), 398-405. DOI: 10.1016/j.jalz.2009.01.025

Outcome over seven years of healthy adults with and without subjective cognitive impairment

Alzheimer`s & Dementia, 2010, 6(1), 11-24. DOI: 10.1016/j.jalz.2009.10.002

A European perspective on population studies of dementia

Alzheimer`s & Dementia, 2011, 7(1), 3-9. DOI: 10.1016/j.jalz.2010.12.003

Operationalizing diagnostic criteria for Alzheimer‘s disease and other age-related cognitive impairment–Part 2

Alzheimer`s & Dementia, 2011, 7(1), 35-52. DOI: 10.1016/j.jalz.2010.12.002

Sources of variability in estimates of the prevalence of Alzheimer‘s disease in the United States

Alzheimer`s & Dementia, 2011, 7(1), 74-79. DOI: 10.1016/j.jalz.2010.11.006

The diagnosis of mild cognitive impairment due to Alzheimer‘s disease: Recommendations from the National Institute on Aging-Alzheimer‘s Association workgroups on diagnostic guidelines for Alzheimer's disease

Alzheimer`s & Dementia, 2011, 7(3), 270-279. DOI: 10.1016/j.jalz.2011.03.008

The measurement of everyday cognition: Development and validation of a short form of the Everyday Cognition scales

Alzheimer`s & Dementia, 2011, 7(6), 593-601. DOI: 10.1016/j.jalz.2011.02.007

Functional deficits among patients with mild cognitive impairment

Alzheimer`s & Dementia, 2011, 7(6), 611-614. DOI: 10.1016/j.jalz.2010.12.011

Mild cognitive impairment: Disparity of incidence and prevalence estimates

Alzheimer`s & Dementia, 2012, 8(1), 14-21. DOI: 10.1016/j.jalz.2011.01.002

Cognitive impairment in nondemented oldest-old: Prevalence and relationship to cardiovascular risk factors

Alzheimer`s & Dementia, 2012, 8(2), 87-94. DOI: 10.1016/j.jalz.2011.02.008

Fornix integrity and hippocampal volume predict memory decline and progression to Alzheimer‘s disease

Alzheimer`s & Dementia, 2012, 8(2), 105-113. DOI: 10.1016/j.jalz.2011.05.2416

An investigation of PreMCI: Subtypes and longitudinal outcomes

Alzheimer`s & Dementia, 2012, 8(3), 172-179. DOI: 10.1016/j.jalz.2011.03.002

Serum antibodies to periodontal pathogens are a risk factor for Alzheimer‘s disease

Alzheimer`s & Dementia, 2012, 8(3), 196-203. DOI: 10.1016/j.jalz.2011.04.006

Comparing new templates and atlas-based segmentations in the volumetric analysis of brain magnetic resonance images for diagnosing Alzheimer‘s disease

Alzheimer`s & Dementia, 2012, 8(5), 399-406. DOI: 10.1016/j.jalz.2011.07.002

A new informant-based questionnaire for instrumental activities of daily living in dementia

Alzheimer`s & Dementia, 2012, 8(6), 536-543. DOI: 10.1016/j.jalz.2011.08.006

Computer-related self-efficacy and anxiety in older adults with and without mild cognitive impairment

Alzheimer`s & Dementia, 2012, 8(6), 544-552. DOI: 10.1016/j.jalz.2011.12.008

The economics of mild cognitive impairment

Alzheimer`s & Dementia, 2013, 9(1), 58-62. DOI: 10.1016/j.jalz.2012.05.2117

Phenotypic regional functional imaging patterns during memory encoding in mild cognitive impairment and Alzheimer's disease

Alzheimer`s & Dementia, 2013, 9(3), 284-294. DOI: 10.1016/j.jalz.2011.12.006

Mild cognitive impairment in a community sample: The Sydney Memory and Ageing Study

Alzheimer`s & Dementia, 2013, 9(3), 310-317. DOI: 10.1016/j.jalz.2011.11.010

Predictors and outcomes for caregivers of people with mild cognitive impairment: A systematic literature review

Alzheimer`s & Dementia, 2013, 9(3), 346-355. DOI: 10.1016/j.jalz.2012.01.012

Long–term anticholinergic use and the aging brain

Alzheimer`s & Dementia, 2013, 9(4), 377-385. DOI: 10.1016/j.jalz.2012.02.005